Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Alloimmunization

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    42 result(s) found for: Alloimmunization. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2010-023955-27 Sponsor Protocol Number: 34760 Start Date*: 2011-04-29
    Sponsor Name:Leiden University Medical Center
    Full Title: Randomized controlled trial on the use of rhEPO to reduce top-up transfusions in neonates with red blood cell alloimmunization
    Medical condition: hemolytic disease of the newborn due to red blood cell alloimmunization
    Disease:
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000968-30 Sponsor Protocol Number: RC31/19/0509 Start Date*: 2021-04-13
    Sponsor Name:CHU Toulouse
    Full Title: ASPirin in Immune thRombocytopenia patients with cardiovascular disEase
    Medical condition: Immune thrombocytopenia with cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    23.0 10005329 - Blood and lymphatic system disorders 10083842 Immune thrombocytopenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-000583-15 Sponsor Protocol Number: 60858 Start Date*: 2017-08-11
    Sponsor Name:Leiden University Medical Center
    Full Title: Randomized controlled trial on the use of EPO to reduce top-up transfusions in neonates with red blood cell alloimmunization treated with intrauterine transfusions
    Medical condition: Hemolytic disease of the newborn due to red blood cell alloimmunization
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10019513 Hemolytic disease of fetus or newborn, due to isoimmunization LLT
    Population Age: Preterm newborn infants, Newborns, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-001627-32 Sponsor Protocol Number: CVAY736Q12301 Start Date*: 2023-03-15
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase 3 randomized, double-blind study of ianalumab (VAY736) versus placebo in addition to eltrombopag in patients with primary immune thrombocytopenia (ITP) who had an insufficient response or r...
    Medical condition: immune thrombocytopenia (ITP)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10005329 - Blood and lymphatic system disorders 10083842 Immune thrombocytopenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) CZ (Trial now transitioned) HU (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned) NL (Trial now transitioned) NO (Trial now transitioned) ES (Ongoing) AT (Trial now transitioned) BE (Trial now transitioned) RO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-001035-20 Sponsor Protocol Number: PIPL002a Start Date*: 2016-06-10
    Sponsor Name:DRK-Blutspendedienst NSTOB
    Full Title: Phase III, randomized, double-blind, multicentre clinical trial on clinical efficacy and safety of platelet concentrates treated with the THERAFLEX UV-Platelets procedure in comparison to conventio...
    Medical condition: Thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10043555 Thrombocytopenias HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004162-18 Sponsor Protocol Number: PDY16894 Start Date*: 2021-03-16
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: A multicenter, Phase 2a, open-label, non-randomized study evaluating the efficacy, safety, and tolerability of BIVV020 in adults with persistent/chronic immune thrombocytopenia (ITP)
    Medical condition: immune thrombocytopenia (ITP)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10005329 - Blood and lymphatic system disorders 10083842 Immune thrombocytopenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) NL (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-000292-37 Sponsor Protocol Number: APHP200017 Start Date*: 2021-06-25
    Sponsor Name:ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS
    Full Title: Intravenous Immunoglobulin plus oral prednisone or high-dose dexamethasone, for adults with immune thrombocytopenia (ITP) with moderate and severe bleeding: a randomized, multicentre trial (IVIORDEX).
    Medical condition: Adult patients with immune thrombocytopenia (ITP) with mild to severe bleeding manifestations.
    Disease: Version SOC Term Classification Code Term Level
    23.0 10005329 - Blood and lymphatic system disorders 10083842 Immune thrombocytopenia PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-000006-16 Sponsor Protocol Number: APHP201098 Start Date*: 2022-01-10
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: A phase 3 randomized and double-blind controlled trial comparing the efficacy and safety of subcutaneous belimumab or placebo in addition to rituximab in adult patients with persistent or chronic i...
    Medical condition: Adults with a definite diagnosis of primary chronic immune thrombocytopeniaaccording to the standard definition. Patients with antinuclear antibodies with no definite criteria for systemic lupus wi...
    Disease: Version SOC Term Classification Code Term Level
    23.0 10005329 - Blood and lymphatic system disorders 10083842 Immune thrombocytopenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-002039-40 Sponsor Protocol Number: CLNP023L12201 Start Date*: 2021-10-29
    Sponsor Name:Novartis Pharma AG
    Full Title: An open-label, multi-center, phase 2 basket study to assess efficacy, safety and pharmacokinetics of iptacopan (LNP023) in participants with autoimmune benign hematological disorders
    Medical condition: Immune thrombocytopenia (ITP) Cold agglutinin disease (CAD)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10005329 - Blood and lymphatic system disorders 10083842 Immune thrombocytopenia PT
    20.0 10005329 - Blood and lymphatic system disorders 10068863 Cold agglutinin disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-003232-24 Sponsor Protocol Number: AVA-PED-301 Start Date*: 2020-12-03
    Sponsor Name:Dova Pharmaceuticals, Inc.
    Full Title: A Phase 3b, Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment...
    Medical condition: Thrombocytopenia in paediatric subjects with immune thrombocytopenia for ≥6 months duration who have had an insufficient response to a previous treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10043555 Thrombocytopenias HLT
    23.0 10005329 - Blood and lymphatic system disorders 10083843 Primary immune thrombocytopenia LLT
    23.0 10005329 - Blood and lymphatic system disorders 10083842 Immune thrombocytopenia PT
    20.0 10005329 - Blood and lymphatic system disorders 10035534 Platelet disorders HLGT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) HU (Completed) DE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2005-000859-15 Sponsor Protocol Number: ML 18542 Start Date*: 2005-04-14
    Sponsor Name:ROCHE
    Full Title: Randomized prospective study comparing dexamethasone and dexamethasone plus rituximab in the treatment of idiopathic thrombocytopenic purpura (ITP) in adults.
    Medical condition: Front-line treatment of adult ITP
    Disease: Version SOC Term Classification Code Term Level
    6.1 10021245 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000172-13 Sponsor Protocol Number: 20030213 Start Date*: 2008-08-20
    Sponsor Name:Amgen Inc.
    Full Title: An Open Label Study Evaluating the Safety and Efficacy of Long-Term Dosing of AMG 531 in Thrombocytopenic Subjects with Immune (Idiopathic) Thrombocytopenic Purpura ( ITP)
    Medical condition: Thrombocytopenia in subjects with Immune Thrombocytopenic Purpura (ITP)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10021245 Idiopathic thrombocytopenic purpura LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) AT (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000638-37 Sponsor Protocol Number: 20040209 Start Date*: 2008-02-28
    Sponsor Name:Amgen Inc.
    Full Title: An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects with Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
    Medical condition: Immune (Idiopathic) Thrombocytopenic Purpura
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021245 Idiopathic thrombocytopenic purpura LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) CZ (Completed) BE (Completed) AT (Completed) IE (Completed) GB (Completed) IT (Completed) ES (Prematurely Ended) SK (Completed)
    Trial results: View results
    EudraCT Number: 2005-003552-35 Sponsor Protocol Number: GAM10-02 Start Date*: 2006-03-28
    Sponsor Name:Octapharma AG
    Full Title: Clinical study to evaluate the efficacy and safety of Octagam® 10% in Idiopathic Thrombocytopenic Purpura in adults.
    Medical condition: Idiopathic thrombocytopenic purpura, in adults actively bleeding or at high risk bleeding.
    Disease: Version SOC Term Classification Code Term Level
    7.0 10021245 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) CZ (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2021-006970-22 Sponsor Protocol Number: 2021-006970-22 Start Date*: 2022-08-18
    Sponsor Name:FISEVI
    Full Title: A multicentre, randomized, open-label study of romiplostim plus dexamethasone vs dexamethasone in patients with newly diagnosed primary immune thrombocytopenia
    Medical condition: Primary immune thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    23.0 10005329 - Blood and lymphatic system disorders 10083842 Immune thrombocytopenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-019987-35 Sponsor Protocol Number: 20080435 Start Date*: 2010-07-23
    Sponsor Name:Amgen Inc
    Full Title: A Phase 2, Interventional, Single Arm Study Describing Platelet Responses and ITP Remission Rates in Adult Subjects with Immune Thrombocytopenia Purpura Receiving Romiplostim.
    Medical condition: Adult immune thrombocytopenic purpura (ITP)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021245 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) DE (Completed) GB (Completed) ES (Completed) FR (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2011-000263-27 Sponsor Protocol Number: IgPro10_4001 Start Date*: 2011-07-22
    Sponsor Name:CSL Behring LLC
    Full Title: An open-label, prospective, multicenter study to investigate the specificity of in vivo antibody binding to red blood cells in subjects with chronic immune thrombocytopenic purpura (ITP) treated wi...
    Medical condition: Chronic immune thrombocytopenic purpura (ITP)
    Disease: Version SOC Term Classification Code Term Level
    15.0 10005329 - Blood and lymphatic system disorders 10021245 Idiopathic thrombocytopenic purpura PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2012-000796-16 Sponsor Protocol Number: GAMr-30 Start Date*: 2012-07-09
    Sponsor Name:OCTAPHARMA AG
    Full Title: PROSPECTIVE, OPEN-LABEL, NON-CONTROLLED, MULTICENTER, PHASE III CLINICAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCTAGAM 10% IN PRIMARY IMMUNE THROMBOCYTOPENIA
    Medical condition: Primary Immune Thrombocytopenia (ITP)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10005329 - Blood and lymphatic system disorders 10023095 ITP LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-004295-22 Sponsor Protocol Number: NL59645.098.16 Start Date*: 2017-04-10
    Sponsor Name:Hagaziekenhuis
    Full Title: Treatment of thromBocytopenia with EltRombopag or Intravenous Immune Globulin (IVIG) Before and DurING Invasive Procedures in Patients with Immune ThrombocytoPenia.
    Medical condition: Immune thrombocytopenia patients with low platelets and in need of surgery.
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004851 10023095 ITP LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-000537-11 Sponsor Protocol Number: ZLB03_003CR Start Date*: 2004-12-01
    Sponsor Name:ZLB Behring AG
    Full Title: An open-label, multicenter study on the efficacy and safety of IgPro10 in patients with chronic immune thrombocytopenic purpura (ITP)
    Medical condition: Immune thrombocytopenic purpura (ITP) is the most common autoimmune disease. It is a bleeding disorder characterized by decreased counts of circulating platelets and normal or increased numbers of ...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 08:24:23 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA